Background
DSU Medical Corporation and Medisystems Corporation held patents on a guarded winged-needle assembly designed to prevent accidental needle-stick injuries during intravenous therapy. The key claim covered a needle set with an attached protective guard that shielded the needle after use. ITL Corporation, an Australian company, manufactured a clamshell-style needle guard called the “Platypus” that was sold to JMS Co., a Japanese medical device company, which then assembled and distributed complete needle sets incorporating ITL’s guard.
At trial, the jury found JMS liable for direct infringement and inducement of infringement, but found ITL not liable. On appeal, both parties challenged portions of the verdict, and the Federal Circuit agreed to hear the inducement question en banc to resolve conflicting signals in its precedents about the level of intent required under 35 U.S.C. § 271(b).
The Court’s Holding
The Federal Circuit en banc clarified that liability for inducing infringement requires a showing that the defendant knew of the patent and actively and knowingly aided and abetted another’s direct infringement — meaning the defendant must specifically intend to cause the acts that constitute direct infringement, with knowledge that those acts will infringe. It is not enough to show that the defendant intended to cause the acts that happen to constitute infringement while remaining indifferent to whether a patent was actually infringed.
The court drew a clear distinction: inducing infringement is not the same as inducing the acts that turn out to infringe. The defendant must have the specific intent to encourage a third party’s direct infringement, which requires knowledge of the patent and a purposeful purpose to cause infringement. Applying this standard, the court affirmed the finding of inducement against JMS because the evidence supported the conclusion that JMS knew of DSU’s patents and specifically encouraged JMS North America to sell infringing needle sets in the U.S. market.
Key Takeaways
- Induced infringement under § 271(b) requires specific intent — the defendant must both know about the patent and specifically intend to encourage another party’s direct infringement.
- Mere knowledge that a product might infringe, without purposeful encouragement of infringing use, is insufficient to establish inducement.
- A parent company or foreign manufacturer can be liable for inducing the infringing acts of a U.S. subsidiary or distributor if it acts with the required specific intent.
- The ruling resolved a circuit-level ambiguity about whether inducement requires intent to infringe or merely intent to perform the acts at issue, landing firmly on the former.
Why It Matters
DSU Medical set the intent standard that governed inducement claims for years before the Supreme Court’s 2011 decision in Global-Tech Appliances v. SEB S.A. added a “willful blindness” gloss. For technology and medical device companies operating global supply chains, the case clarified when a foreign manufacturer or component supplier can be pulled into U.S. patent litigation based on the downstream activities of its customers.
The ruling is particularly significant for the growing universe of cases involving products sold through distribution chains: a company that simply makes and sells a product to someone who then infringes a patent is not automatically an inducer — there must be evidence of active encouragement and knowledge of the patent. This distinction between neutral commercial conduct and purposeful facilitation of infringement remains a key battleground in modern patent suits involving software, pharmaceuticals, and complex technology products.